A study tissue shows no IHC staining. Is the target genuinely absent, present below the detection limit, or simply not detectable after the way this specimen was handled? An appropriate positive control is the first useful comparison, but it is not the end of the investigation. The same choice of control also matters when establishing a new assay, comparing tissues or assessing a faint, focal signal.

Choosing positive control tissue for IHC means selecting material that answers the specific experimental question. Reliable protein-localization evidence, species compatibility, processing history and expression level each affect what the control can tell you. A bright stain is helpful; a biologically and technically well-matched control is more informative [1,2].

In This Article

  1. What Does a Positive Control Actually Prove?
  2. Choosing Positive Control Tissue That Answers the Right Question
  3. Internal Controls, External Tissues, and Cell Pellets
  4. When the Control Stains but the Sample Does Not
  5. When Another Control or Validation Method Is Worth Adding
  6. Conclusion

1. What Does a Positive Control Actually Prove?

A positive tissue control is most useful when target expression and the expected cellular and subcellular staining pattern are well characterized. Staining in that pattern supports the performance of the assay under the tested conditions, but does not prove that the antibody has no off-target interactions or that a separately processed negative sample has preserved its antigen [1].

Expression level deserves its own consideration. A highly expressing tissue may stain strongly even when the assay is not sufficiently sensitive for a weak endogenous target. A characterized lower-expression control can help probe that limitation if low-level detection is central to the study. This is a method-validation principle, not a requirement to find a weak control for every routine IHC run [1,2].

A successful external control cannot rule out preanalytical problems in the study specimen. Fixation conditions, processing and storage can alter antigenicity, so a separately prepared control may stain as expected while a study sample has reduced detectable antigen [1,2]. Without additional evidence, 'no staining detected under the conditions tested' is more defensible than claiming absolute absence of the protein.

2. Choosing Positive Control Tissue That Answers the Right Question

Start with credible protein-level evidence of expression and the expected location of the signal. Target-specific IHC expression profiles, such as the CTSG guide, can show which cell populations are reported to express a protein; they are useful leads, not a guarantee that an unrelated antibody will stain the same tissues. Prefer candidates with a reasonably established cellular and subcellular pattern, so that both the presence and the location of staining can be judged [1].

For markers restricted to particular immune-cell populations, for example, a lymphoid tissue may be useful precisely because the anticipated positive cells can be distinguished from neighboring cells. That spatial pattern gives more information than diffuse staining across an entire section. Transcript atlases can suggest candidates, but mRNA abundance alone does not verify protein-level IHC staining or a particular antibody's performance [1].

Once expression is supported, check species compatibility before choosing the material. Human tissue staining does not establish that the same antibody performs in mouse, rat or another species. Sequence or epitope similarity may suggest cross-reactivity, but suitable same-species material—or independent species-specific validation—is the stronger basis for a positive control [1].

Then compare processing conditions. For an FFPE study section, an FFPE control with reasonably comparable fixation and embedding history is generally more informative than a differently processed specimen. Archival material may not allow close matching; that difference should be acknowledged when interpreting a negative result. Antigen retrieval conditions can affect epitope access, but must be appropriate for the particular antibody and tissue rather than treated as a universal remedy [1,2].

Finally, choose an expression level relevant to the intended interpretation. A high-positive tissue provides a useful signal check; a well-characterized lower-positive tissue may give additional information when the assay must distinguish low expression from no detectable signal. The key is independent evidence of the control's expected expression—not merely picking a section that happens to look faint [1,2].

3. Internal Controls, External Tissues, and Cell Pellets

An internal positive control is a cell population within the study section that is independently expected to express the target. As with other IHC positive and negative controls, its value depends on the question it is meant to answer. It shares much of the specimen's handling history and may therefore reveal sample-specific problems that an external slide cannot. It is informative only if that cell population should truly express the protein in the biological setting being studied [1,2].

An external tissue control is a separate specimen with established target expression. Stained in the same run, it helps assess the assay's performance; when its processing is comparable, the comparison becomes more informative. It cannot establish that antigen was preserved in the individual study specimen [1,2].

Cell pellets can help when well-characterized positive tissue is scarce. A cell line confirmed to express the target may provide a reproducible source of material, and paired low- and high-expression lines can help explore the assay's useful sensitivity. For tissue IHC, those cells require sample preparation compatible with the study specimens, including fixation and embedding where relevant. Overexpression controls require particular caution: an intense signal in transfected cells can overstate how well the assay detects endogenous protein in tissue. Cell pellets also cannot reproduce the full diversity of potential off-target interactions in a multicellular organ [1].

These forms of control answer different questions. A cell pellet can help show that an antibody recognizes an experimentally characterized target; an external tissue control monitors the staining run; an internal tissue control can strengthen interpretation of the individual specimen. None, on its own, proves complete antibody specificity or rules out non-specific IHC staining.

4. When the Control Stains but the Sample Does Not

A negative sample should be read alongside what its controls actually establish. The combinations below distinguish a poorly supported negative result from one that has been tested under more informative conditions; none is a universal diagnosis.

Observed result What the result supports What still needs consideration
Positive control negative; study sample negative The run lacks the expected positive evidence for detection Control suitability, reagent performance, retrieval and staining procedure
Strong positive control positive; study sample negative The method detects abundant control antigen under those conditions Weak-target sensitivity, sample processing and true target expression
Strong positive control positive; characterized low-positive control negative Detection of weak expression may be inadequate under the tested conditions Assay optimization and low-level antigen preservation
External control positive; expected internal control negative The external run control worked, but specimen-level interpretation remains uncertain Fixation, antigenicity and whether internal expression was truly expected
Controls behave as expected; study sample negative Confidence in the negative finding increases Assay detection limits, heterogeneity and independent target evidence

The first division is whether the assay demonstrated the expected positive signal at all. If it did not, the sample's negative result is not yet interpretable. If a suitable control did stain, the next questions are whether the assay was sensitive enough for the target level of interest and whether the sample itself retained detectable antigen. When these conditions are adequately supported, the negative observation carries more weight—but remains a statement about detectable immunostaining, not absolute protein absence [1,2].

If only an intensely positive control stains while an independently characterized lower-positive material does not, investigate sensitivity before simply restaining the same sample. The same reasoning applies to weak or absent IHC staining: first identify which aspect of the assay remains uncertain, then select a test that addresses it.

5. When Another Control or Validation Method Is Worth Adding

Not every target has an obvious positive tissue. When published protein-localization data are limited, a cell line with independently established expression may be a practical alternative. If the only candidate tissue is from another species, verify cross-species antibody performance rather than treating a predicted epitope match as proof [1].

If an external tissue control stains but the study sample remains negative, useful IHC troubleshooting should address the actual gap in evidence. Suspected processing differences call for a closer assessment of antigen preservation; uncertain sensitivity calls for suitable lower-expression material; uncertain specificity may call for genetic material, a second epitope or an orthogonal assay [1]. KO/KD antibody validation can support some of these strategies, but evidence must still be assessed for the intended application.

Complementary methods also need careful interpretation. Western blotting or RNA analysis may support target expression, but their bulk measurements can miss a small cell population and do not reproduce IHC's spatial information. application-specific antibody validation matters because the same antibody may behave differently across assay conditions. The next method should be chosen for the uncertainty it can resolve, not simply to add another result [1].

Conclusion

A useful IHC positive control is selected for the question it can answer. Protein localization, species, processing and expression level determine whether a strong signal provides only a basic run check or meaningful support for a particular study. Internal, external and cell-based controls contribute different pieces of that evidence; none replaces thoughtful validation of the assay [1,2].

When a sample stains negative, the strongest conclusion is that no target-associated staining was detected under suitably evaluated conditions—not that the target must be absent. Good control selection makes that conclusion more defensible, while remaining useful across assay development, tissue comparison and low-expression studies.

References

1. Webster JD, Solon M, Gibson-Corley KN. Validating Immunohistochemistry Assay Specificity in Investigative Studies: Considerations for a Weight of Evidence Approach. Veterinary Pathology. 2021;58(5):829–840. doi:10.1177/0300985820960132. Journal article

2. Verbeke H, Van Hecke D, Bauraing C, et al. Belgian Recommendations for Analytical Verification and Validation of Immunohistochemical Tests in Laboratories of Anatomic Pathology. Applied Immunohistochemistry & Molecular Morphology. 2024;32(1):1–16. doi:10.1097/PAI.0000000000001165. Journal article

3. Aeffner F, Bolon B, Boyle MH, et al. Scientific and Regulatory Policy Committee Points to Consider: Sample Selection, Assay Design, Data Generation and Interpretation, and Reporting Practices for Chromogenic Immunohistochemical (IHC) Assays in Nonclinical Drug Development. Toxicologic Pathology. 2026;54(3):233–266. doi:10.1177/01926233251393154. Journal article: https://doi.org/10.1177/01926233251393154